Brief: Cingulate Completes Pre-NDA Meeting With FDA To Discuss New Drug Application For Lead ADHD Asset CTX-1301
03/04/2025 13:09
April 3 (Reuters) - Cingulate Inc CING.O: CINGULATE COMPLETES PRE-NDA MEETING WITH FDA TO DISCUSS NEW DRUG APPLICATION FOR LEAD ADHD ASSET CTX-1301 Source text: ID:nGNX5DHDMj Further company coverage: CING.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)